AU2001235691A1 - Use of paullone derivatives for making medicines - Google Patents
Use of paullone derivatives for making medicinesInfo
- Publication number
- AU2001235691A1 AU2001235691A1 AU2001235691A AU3569101A AU2001235691A1 AU 2001235691 A1 AU2001235691 A1 AU 2001235691A1 AU 2001235691 A AU2001235691 A AU 2001235691A AU 3569101 A AU3569101 A AU 3569101A AU 2001235691 A1 AU2001235691 A1 AU 2001235691A1
- Authority
- AU
- Australia
- Prior art keywords
- making medicines
- paullone derivatives
- paullone
- derivatives
- medicines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0001862 | 2000-02-15 | ||
FR0001862A FR2804959B1 (en) | 2000-02-15 | 2000-02-15 | USE OF PAULLON DERIVATIVES FOR THE MANUFACTURE OF MEDICAMENTS |
PCT/FR2001/000455 WO2001060374A1 (en) | 2000-02-15 | 2001-02-15 | Use of paullone derivatives for making medicines |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001235691A1 true AU2001235691A1 (en) | 2001-08-27 |
Family
ID=8847019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001235691A Abandoned AU2001235691A1 (en) | 2000-02-15 | 2001-02-15 | Use of paullone derivatives for making medicines |
Country Status (7)
Country | Link |
---|---|
US (1) | US7232814B2 (en) |
EP (1) | EP1255551A1 (en) |
JP (1) | JP2003522793A (en) |
AU (1) | AU2001235691A1 (en) |
CA (1) | CA2397560A1 (en) |
FR (1) | FR2804959B1 (en) |
WO (1) | WO2001060374A1 (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2806626B1 (en) * | 2000-03-22 | 2003-11-28 | Centre Nat Rech Scient | USE OF MODULATING SUBSTANCES FOR THE EXPRESSION OR FUNCTION OF A PROTEIN INVOLVED IN THE CELL CYCLE FOR THE TREATMENT OR PREVENTION OF ACUTE NEURAL INJURIES |
WO2002030410A2 (en) * | 2000-10-10 | 2002-04-18 | Board Of Regents, The University Of Texas System | Suppression of cyclin kinase activity for prevention and treatment of infections |
EP1295884A1 (en) * | 2001-09-21 | 2003-03-26 | Sanofi-Synthelabo | 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives |
WO2003027115A1 (en) | 2001-09-21 | 2003-04-03 | Sanofi-Synthelabo | Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders |
EP1494757A2 (en) * | 2002-04-04 | 2005-01-12 | Enzon, Inc. | Polymeric acyl derivatives of indoles |
EP1925306A3 (en) * | 2002-04-30 | 2008-09-17 | Alcon, Inc. | Agents which Regulate, Inhibit, or Modulate the Activity and/or Expression of Connective Tissue Growth Factor (CTGF) to Lower Intraocular Pressure |
JP2005523928A (en) | 2002-04-30 | 2005-08-11 | アルコン,インコーポレイテッド | Modulates, inhibits, or modulates the activity and / or expression of connective tissue growth factor (CTGF) as a unique means for both reducing intraocular pressure and treating glaucomatous retinopathy / optic neuropathy Drugs |
DE10260618B4 (en) * | 2002-12-23 | 2005-06-09 | Faustus Forschungs Cie. Translational Cancer Research Gmbh | Tumor-inhibiting fused azepinone derivatives |
WO2004100977A1 (en) * | 2003-03-25 | 2004-11-25 | The Board Of Trustees Of The University Of Illinois | Inhibition of tumor cell proliferation by foxm1b inhibitors |
AU2005239811B2 (en) * | 2004-05-12 | 2010-06-17 | Bayer Cropscience Ag | Plant growth regulation |
US20110293746A1 (en) * | 2004-07-09 | 2011-12-01 | Agency For Science, Technology And Research | Modulation of Gsk-3Beta and Method of Treating Proliferative Disorders |
WO2006024947A2 (en) * | 2004-09-02 | 2006-03-09 | Neuro Therapeutics Ab | Methods and materials relating to enhanced production of dopamine neurons |
CN101068815B (en) * | 2004-10-04 | 2012-09-05 | 千禧药品公司 | Lactam compounds useful as protein kinase inhibitors |
FR2876584B1 (en) * | 2004-10-15 | 2007-04-13 | Centre Nat Rech Scient Cnrse | USE OF KENPAULLONE FOR THE PRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF MUCOVISCIDOSIS AND DISEASES ASSOCIATED WITH A DEFECT OF ADDRESSING PROTEINS IN CELLS |
ATE542535T1 (en) * | 2005-05-04 | 2012-02-15 | Develogen Ag | USE OF AZAPAULLONE FOR THE PREVENTION AND TREATMENT OF PANCREATIC AUTOIMMUNE DISEASES |
EP1885454A2 (en) | 2005-05-04 | 2008-02-13 | DeveloGen Aktiengesellschaft | Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders |
JP2009501176A (en) * | 2005-07-12 | 2009-01-15 | アボット ゲーエムベーハー ウント カンパニー カーゲー | Pyridazine compounds as glycogen synthase kinase 3 inhibitors |
EP1757607A1 (en) | 2005-08-24 | 2007-02-28 | Molisa GmbH | N5-substituted benzo¬2,3|azepino¬4,5-b|indol-6-ones for treating tropical diseases |
JP2009506069A (en) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | Neurogenesis through modulation of muscarinic receptors |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
FR2899107B1 (en) * | 2006-03-30 | 2008-06-13 | Neurokin Entpr Unipersonnelle | USE OF (S) -ROSCOVITINE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
US8029980B2 (en) | 2006-09-29 | 2011-10-04 | The Board Of Trustees Of The University Of Illinois | Identification and use of agents that modulate oncogenic transcription agent activity |
WO2008097861A2 (en) * | 2007-02-02 | 2008-08-14 | Braincells, Inc. | MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS |
WO2009010298A2 (en) * | 2007-07-18 | 2009-01-22 | Technische Universität Carolo-Wilhelmina Zu Braunschweig | Paullone derivatives and its use |
EP3078738B1 (en) | 2007-08-31 | 2020-05-20 | Whitehead Institute for Biomedical Research | Wnt pathway stimulation in reprogramming somatic cells |
US20120010178A1 (en) * | 2008-10-21 | 2012-01-12 | President And Fellows Of Harvard College | Methods and compounds for treatment of neurodegenerative disorders |
AR074487A1 (en) * | 2008-12-05 | 2011-01-19 | Millennium Pharm Inc | PLK PROTEINQUINASH INHIBITING TIOLACTAMAS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES OF THE SAME FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DISORDERS, IN PARTICULAR CANCER. |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
US20110088107A1 (en) * | 2009-04-24 | 2011-04-14 | Yaqub Hanna | Compositions and methods for deriving or culturing pluripotent cells |
WO2014145205A2 (en) | 2013-03-15 | 2014-09-18 | St. Jude Children's Research Hospital | Methods and compositions of p27kip1 transcription modulators |
WO2016205806A1 (en) | 2015-06-18 | 2016-12-22 | St. Jude Children's Research Hospital | Methods and compositions for the prevention and treatment of hearing loss |
WO2016201581A1 (en) | 2015-06-18 | 2016-12-22 | The Hospital For Sick Children | Method of treating medulloblastoma |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9721437D0 (en) * | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
EP1086105B1 (en) * | 1998-06-16 | 2006-03-01 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Fused azepinone cyclin dependent kinase inhibitors |
-
2000
- 2000-02-15 FR FR0001862A patent/FR2804959B1/en not_active Expired - Fee Related
-
2001
- 2001-02-15 US US10/203,977 patent/US7232814B2/en not_active Expired - Fee Related
- 2001-02-15 EP EP01907815A patent/EP1255551A1/en not_active Ceased
- 2001-02-15 AU AU2001235691A patent/AU2001235691A1/en not_active Abandoned
- 2001-02-15 JP JP2001559470A patent/JP2003522793A/en active Pending
- 2001-02-15 CA CA002397560A patent/CA2397560A1/en not_active Abandoned
- 2001-02-15 WO PCT/FR2001/000455 patent/WO2001060374A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP1255551A1 (en) | 2002-11-13 |
CA2397560A1 (en) | 2001-08-23 |
US7232814B2 (en) | 2007-06-19 |
WO2001060374A1 (en) | 2001-08-23 |
US20030181439A1 (en) | 2003-09-25 |
FR2804959A1 (en) | 2001-08-17 |
FR2804959B1 (en) | 2006-04-28 |
JP2003522793A (en) | 2003-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001235691A1 (en) | Use of paullone derivatives for making medicines | |
AU2002363005A1 (en) | Derivatives of uk-2a | |
AU2001269529A1 (en) | Medicine comprising dicyanopyridine derivative | |
AU2001280099A1 (en) | 4-acylaminopyrazole derivatives | |
AU2001230584A1 (en) | 1h-imidazopyridine derivatives | |
AU2177001A (en) | Use of indirubine derivatives for making medicines | |
AU2001230537A1 (en) | Pyridoxazine derivatives | |
AU2001281802A1 (en) | 6-phenylpyrrolopyrimidinedione derivatives | |
AU2001278790A1 (en) | 1h-imidazopyridine derivatives | |
AU2001278694A1 (en) | Avermectin derivatives | |
AU2001264280A1 (en) | Vitamin D derivatives | |
AU2002213978A1 (en) | Substituted C-cyclohexylmethylamine derivatives | |
AU2002232468A1 (en) | Pharmaceutical heterocyclic compounds | |
AU2002212301A1 (en) | Diazacycloalkanedione derivatives | |
AU2002212959A1 (en) | Cycloalkylfluorosulfonamide derivatives | |
AU2001232948A1 (en) | Controlled release of drugs | |
AU2002215212A1 (en) | 1-methylcarbapenem derivatives | |
AU2001292122A1 (en) | Heterocyclic derivatives useful as pharmaceutical agents | |
AU2001289937A1 (en) | Substituted 1-aminobutan-3-ol derivatives | |
AU2001254661A1 (en) | Aminosulfonylbiphenyl derivatives | |
AU2001230565A1 (en) | Perfluoroisopropylbenzene derivatives | |
AU2001234313A1 (en) | Novel phenylheteroalkylamine derivatives | |
AU2001242772A1 (en) | 3-substituted-4-pyrimidone derivatives | |
AU2001291691A1 (en) | Drugs for incontinence | |
AU2001292578A1 (en) | Pharmaceutical compounds |